Cargando…

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia

BACKGROUND: Atypical chronic myeloid leukemia (aCML) is a rare myelodysplastic/myeloproliferative neoplasm. There is no proven standard of care treatment and the only curative option available is hematopoietic stem cell transplant. In addition to traditional chemotherapy, targeted therapy has shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandow, Lyndsey, Heinrich, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248858/ https://www.ncbi.nlm.nih.gov/pubmed/37305181 http://dx.doi.org/10.1016/j.lrr.2023.100371

Ejemplares similares

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation
por: Rai, Shinya, et al.
Publicado: (2021)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia
por: Lopes, Marta, et al.
Publicado: (2018)

De novo Leukemic Variant of Mast Cell Leukemia With KIT D816V
por: Bang, Hae In, et al.
Publicado: (2015)

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V
por: Rai, Shinya, et al.
Publicado: (2020)

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
por: Kampa-Schittenhelm, Kerstin M., et al.
Publicado: (2018)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation
por: Suh, Myung Chul, et al.
Publicado: (2017)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS
por: Chi, Susan, et al.
Publicado: (2021)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
por: Wang, Biao, et al.
Publicado: (2020)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
por: Tobío, Araceli, et al.
Publicado: (2020)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
por: Cho, Byung-Sik, et al.
Publicado: (2021)

The spleen microenvironment influences disease transformation in a mouse model of KIT(D816V)-dependent myeloproliferative neoplasm
por: Pelusi, Natalie, et al.
Publicado: (2017)

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT
por: Bandara, Geethani, et al.
Publicado: (2018)

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
por: Grootens, Jennine, et al.
Publicado: (2019)

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation
por: Trullas-Jimeno, A., et al.
Publicado: (2021)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
por: Cocorocchio, Emilia, et al.
Publicado: (2020)

Photosensitivity From Avapritinib: Pharamacovigilance Analysis
por: Venkatakrishnan, Ajit, et al.
Publicado: (2022)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

Differential Effects of CSF-1R D802V and KIT D816V Homologous Mutations on Receptor Tertiary Structure and Allosteric Communication
por: Da Silva Figueiredo Celestino Gomes, Priscila, et al.
Publicado: (2014)

XK-related protein 5 (XKR5) is a novel negative regulator of KIT/D816V-mediated transformation
por: Sun, Jianmin, et al.
Publicado: (2018)

Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report
por: Malik, Faizan, et al.
Publicado: (2017)

Discovery of novel heteroaryl alkynes for highly potent KIT(D816V) cells inhibition to treat gastrointestinal stromal tumors
por: Xie, Zhicheng, et al.
Publicado: (2022)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
por: Jones, Robin L., et al.
Publicado: (2021)

A typical atypical chronic myeloid leukemia
por: Gilioli, Andrea, et al.
Publicado: (2018)

The mutational landscape of atypical chronic myeloid leukemia
por: Langabeer, Stephen E.
Publicado: (2019)

Mutation D816V Alters the Internal Structure and Dynamics of c-KIT Receptor Cytoplasmic Region: Implications for Dimerization and Activation Mechanisms
por: Laine, Elodie, et al.
Publicado: (2011)

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
por: Rupar, Kaja, et al.
Publicado: (2018)

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase
por: Bibi, Siham, et al.
Publicado: (2016)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

Avapritinib-induced photo-aggravated cutaneous reaction
por: Dadrass, Farinoosh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ml9qmhs9t6ukaglgl5nuidqea7